STAAR SURGICAL CO (STAA) Stock Price, Forecast & Analysis
USA - NASDAQ:STAA - US8523123052 - Common Stock
STAA Key Statistics, Chart & Performance
The current stock price of STAA is 27.41 USD. In the past month the price increased by 0.59%. In the past year, price increased by 2.81%.
STAA Latest News, Press Relases and Analysis
STAA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.59 | 14.06B | ||
| SOLV | SOLVENTUM CORP | 12.09 | 12.45B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.29 | 10.02B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.74 | 5.23B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.51 | 3.45B | ||
| ICUI | ICU MEDICAL INC | 17.49 | 3.44B | ||
| HAE | HAEMONETICS CORP/MASS | 14.68 | 3.40B | ||
| XRAY | DENTSPLY SIRONA INC | 6.96 | 2.19B | ||
| UFPT | UFP TECHNOLOGIES INC | 27.18 | 1.81B | ||
| NEOG | NEOGEN CORP | 21.2 | 1.38B | ||
| EMBC | EMBECTA CORP | 4.68 | 799.56M | ||
| BVS | BIOVENTUS INC - A | 12.69 | 619.27M |
Related stock screener links
About STAA
Company Profile
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Company Info
STAAR SURGICAL CO
1911 Walker Ave
Monrovia California CALIFORNIA 92630 US
CEO: Caren Mason
Employees: 1157
Phone: 16263037902
STAAR SURGICAL CO / STAA FAQ
What does STAA do?
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
What is the current price of STAA stock?
The current stock price of STAA is 27.41 USD. The price increased by 3.24% in the last trading session.
Does STAA stock pay dividends?
STAA does not pay a dividend.
What is the ChartMill technical and fundamental rating of STAA stock?
STAA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of STAAR SURGICAL CO (STAA) based on its PE ratio?
STAAR SURGICAL CO (STAA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.19).
Can you provide the market cap for STAAR SURGICAL CO?
STAAR SURGICAL CO (STAA) has a market capitalization of 1.35B USD. This makes STAA a Small Cap stock.
Can you provide the short interest for STAA stock?
The outstanding short interest for STAAR SURGICAL CO (STAA) is 8.18% of its float.
STAA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to STAA. When comparing the yearly performance of all stocks, STAA is a bad performer in the overall market: 61.32% of all stocks are doing better.
STAA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to STAA. While STAA has a great health rating, there are worries on its profitability.
STAA Financial Highlights
Over the last trailing twelve months STAA reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -223.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.76% | ||
| ROE | -28.31% | ||
| Debt/Equity | 0 |
STAA Forecast & Estimates
14 analysts have analysed STAA and the average price target is 25.12 USD. This implies a price decrease of -8.36% is expected in the next year compared to the current price of 27.41.
For the next year, analysts expect an EPS growth of -478.33% and a revenue growth -25.47% for STAA